# Abbott Laboratories vs Gilead Sciences: stocks compared

URL: https://funkfolio.com/compare/abt-vs-gild

> Abbott Laboratories ($181.4B, P/E 40.1) and Gilead Sciences ($211.2B) compared: size, valuation, margins, debt, cash and price change.

---

## Abbott Laboratories vs Gilead Sciences

Abbott Laboratories (ABT), health care, and Gilead Sciences (GILD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Gilead Sciences is worth $211.2B on the stock market and Abbott Laboratories $181.4B: Gilead Sciences is valued at 16% more. Abbott Laboratories's operating margin in its latest fiscal year was 18.2% and Gilead Sciences's 34.0%. Over the past year Abbott Laboratories's share price has moved -17.3% and Gilead Sciences's +31.8%.

### Key facts

- **Abbott Laboratories market value:** $181.4B
- **Gilead Sciences market value:** $211.2B
- **Abbott Laboratories P/E:** 40.1
- **Abbott Laboratories revenue:** $44.3B FY to 2025-12-31
- **Gilead Sciences revenue:** $29.4B FY to 2025-12-31
- **Superinvestors holding both:** 3

Market values as of 18 Nov 2026, 04:45 UTC.

Abbott Laboratories vs Gilead Sciences: every measure side by side

| Measure | Abbott Laboratories | Gilead Sciences |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $181.4B lower | $211.2B higher |
| Revenue | $44.3B higher | $29.4B lower |
| Earnings | $6.5B lower | $8.5B higher |
| Employees | 122,000 higher | 17,000 lower |
| Total assets | $86.7B higher | $59B lower |
| Valuation |  |  |
| P/E | 40.1 | — |
| P/S | 4.1 lower | 7.2 higher |
| P/B | 3.6 lower | 16.2 higher |
| Dividend yield | 2.35% higher | 1.94% lower |
| Profitability |  |  |
| Operating margin | 18.2% lower | 34.0% higher |
| Balance sheet |  |  |
| Net assets | $52.1B higher | $22.7B lower |
| Total liabilities | $33.9B lower | $36.4B higher |
| Total debt | $12.9B lower | $24.9B higher |
| Cash on hand | $8.5B higher | $7.6B lower |
| Price change |  |  |
| Today | -2.55% lower | +1.60% higher |
| 1 year | -17.3% lower | +31.8% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Abbott Laboratories 80.5, Gilead Sciences 137.2.

- Abbott Laboratories (ABT)
- Gilead Sciences (GILD)

Abbott Laboratories and Gilead Sciences share prices over one year, rebased to 100: Abbott Laboratories ends at 80.5, Gilead Sciences at 137.2.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ABT | GILD |
| --- | --- | --- |
| Nov 28, 2025 | 99.1 | 101.4 |
| Dec 31, 2025 | 96.4 | 98.9 |
| Jan 30, 2026 | 84.1 | 114.4 |
| Feb 27, 2026 | 89.5 | 120.0 |
| Mar 31, 2026 | 79.0 | 112.3 |
| Apr 30, 2026 | 69.8 | 105.4 |
| May 29, 2026 | 65.8 | 108.3 |
| Jun 30, 2026 | 69.8 | 101.8 |
| Jul 31, 2026 | 81.3 | 104.9 |
| Aug 31, 2026 | 84.9 | 117.9 |
| Sep 30, 2026 | 76.0 | 120.1 |
| Oct 30, 2026 | 81.7 | 137.5 |
| Nov 17, 2026 | 80.5 | 137.2 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (3)

- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.5% / 0.9%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.4% / 0.3%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2% / 0.3%

#### Abbott Laboratories only (12)

- [Mason Hawkins](https://funkfolio.com/gurus/mason-hawkins) 4.0%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 2.4%
- [Diamond Hill team](https://funkfolio.com/gurus/diamond-hill) 2.2%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 1.9%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) 0.7%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.3%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 0.1%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.1%
- [Thomas Russo](https://funkfolio.com/gurus/thomas-russo) &lt;0.1%
- [Howard Gleicher](https://funkfolio.com/gurus/howard-gleicher) &lt;0.1%

#### Gilead Sciences only (7)

- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.7%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 0.7%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.4%
- [John Rogers](https://funkfolio.com/gurus/john-rogers) 0.3%
- [Fred DiSanto](https://funkfolio.com/gurus/fred-disanto) 0.3%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.2%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.2%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Abbott Laboratories / Gilead Sciences). [Who owns ABT](https://funkfolio.com/stock/ABT/superinvestors) · [Who owns GILD](https://funkfolio.com/stock/GILD/superinvestors)

### More on Abbott Laboratories

- [Abbott Laboratories (ABT) stock page](https://funkfolio.com/stock/ABT)
- [Abbott Laboratories market cap](https://funkfolio.com/stock/ABT/market-cap)
- [Abbott Laboratories revenue](https://funkfolio.com/stock/ABT/revenue)
- [Abbott Laboratories P/E ratio](https://funkfolio.com/stock/ABT/pe-ratio)
- [Abbott Laboratories operating margin](https://funkfolio.com/stock/ABT/operating-margin)
- [Abbott Laboratories total debt](https://funkfolio.com/stock/ABT/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Gilead Sciences

- [Gilead Sciences (GILD) stock page](https://funkfolio.com/stock/GILD)
- [Gilead Sciences market cap](https://funkfolio.com/stock/GILD/market-cap)
- [Gilead Sciences revenue](https://funkfolio.com/stock/GILD/revenue)
- [Gilead Sciences P/E ratio](https://funkfolio.com/stock/GILD/pe-ratio)
- [Gilead Sciences operating margin](https://funkfolio.com/stock/GILD/operating-margin)
- [Gilead Sciences total debt](https://funkfolio.com/stock/GILD/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Abbott Laboratories against its closest peers

- [Abbott Laboratories vs Novo Nordisk](https://funkfolio.com/compare/abt-vs-nvo)
- [Abbott Laboratories vs Pfizer](https://funkfolio.com/compare/abt-vs-pfe)
- [Abbott Laboratories vs Danaher](https://funkfolio.com/compare/abt-vs-dhr)

#### Gilead Sciences against its closest peers

- [Gilead Sciences vs Amgen](https://funkfolio.com/compare/amgn-vs-gild)
- [Gilead Sciences vs Thermo Fisher Scientific](https://funkfolio.com/compare/gild-vs-tmo)
- [Gilead Sciences vs Novo Nordisk](https://funkfolio.com/compare/gild-vs-nvo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Abbott Laboratories or Gilead Sciences?**

By market value, Gilead Sciences is the larger: $211.2B against $181.4B for Abbott Laboratories. By revenue in its latest fiscal year, Abbott Laboratories is the larger: $44.3B against $29.4B for Gilead Sciences.

**Which has the higher operating margin?**

Gilead Sciences: 34.0%, against 18.2% for Abbott Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has the higher dividend yield?**

Abbott Laboratories: 2.35%, against 1.94% for Gilead Sciences. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Gilead Sciences: $24.9B, against $12.9B for Abbott Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Abbott Laboratories and Gilead Sciences?**

In their latest 13F filings, Brandon Haley, Ken Griffin and Steve Cohen hold both.

### Cite this page

Funkfolio, “Abbott Laboratories vs Gilead Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/abt-vs-gild

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
